The most common side effects from Abiraterone are diarrhoea, fluid in legs and feet, low blood potassium, urinary tract infection, high blood pressure and bone fractures. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Anyone you share the following link with will be able to read this content: Sorry, a shareable link is not currently available for this article. chemotherapy. Sechenov First Moscow State Medical University, Moscow, Russia, Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan, Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany, You can also search for this author in No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician. PMC The investigators of the STAMPEDE program continue to make practice-changing discoveries that are meaningful and improve survival in this population, and we welcome these results. Management of advanced prostate cancer: A systematic review of existing guidelines and recommendations. Lancet Oncol. Thirty-four patients received abiraterone and 32 received enzalutamide after treatment with second-line flutamide for castration-resistant prostate cancer. Patients who did not have mCRPC or those who received both E and AA were excluded from the study. Stang A. Wenzel M, Wrnschimmel C, Nocera L, Coll Ruvolo C, Tian Z, Shariat SF, et al. PLUS, the latest news on medical advances and breakthroughs from Harvard Medical School experts. Plus, get a FREE copy of the Best Diets for Cognitive Fitness. With the recent use of E and AA in hormone sensitive patients, the question is whether our real-world data will be compatible with the results of randomized prospective studies in the literature. Treatments that block testosterone production in the testicles and other glands are called androgen deprivation therapies, or ADT. Epub 2014 Aug 6. Automating network meta-analysis. Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry. Several pilot studies have shown that both drugs contribute significantly to overall survival (OS). Such difference may be marginal. In the real-world studies performed with E, the most noticeable side effect was fatigue, which was higher than that found in phase 3 prospective trials. https://doi.org/10.1177/1078155220929414 (2020). found a significant difference in PFS between E and AA treatment in docetaxel-naive mCRPC patients (median PFS, E vs. AA; 11.6 vs. 9.0months, p=0.014). Prostate cancer is the second most common cancer in men worldwide1. Google Scholar. The number of patients with no PSA decline was higher in the AA group than that in the E group, and the proportion of patients with a PSA decline of50% was higher in the E group (p=0.020) (Fig. Front Pharmacol. A total of 250 patients treated with E or AA in 5 centers were included. J. Med. With the positive results obtained in COU AA 302 and PREVAIL, AA and E were approved in the pre-docetaxel setting. In December, researchers reported findings from a study showing that the drug abiraterone halves the risk of prostate cancer death among a specific group of patients who previously would not have been treated with it. Google Scholar. The exception consisted of darolutamide. . Since E or AA are not reimbursed in our country, no patients with hormone sensitive prostate cancer (mHSPC) received these treatments. Commun. 2011;364:19952005. BMJ (Clin Res ed). Fizazi, K. et al. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Rcker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. ISSN 1365-7852 (print), https://doi.org/10.1038/s41391-020-0222-6, Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study), The impact of locoregional treatments for metastatic castration resistant prostate cancer on disease progression: real life experience from a multicenter cohort, Editor summary: A paradigm shift in castration-resistant prostate cancer management, Functional roles of E3 ubiquitin ligases in prostate cancer, Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents, Castration-resistant prostate cancer management. Bookshelf The relative treatment effects were presented as HRs and 95% credible interval (CrI). However, study designs differed with respect to PSA- DT definitions. Herein we aimed to compare E and AA in terms of baseline patient characteristics, efficacy and survival in mCRPC patients. Prostate-specific antigen-progression-free survival during . The findings of these three RCTs have been repeatedly updated with the availability of progressively longer follow-up. In the subgroup of PSA-doubling time (PSA-DT)6 months patients, enzalutamide ranked first, followed by darolutamide and apalutamide in that order. 21 February 2022, Get just this article for as long as you need it, Prices may be subject to local taxes which are calculated during checkout. Though initially effective, a subset of patients will develop resistance to ADTs and the tumors will transition to Castration-Resistant . To compare enzalutamide (E) and abiraterone acetate (AA) in terms of efficacy, survival and to characterize prognostic factors affecting survival in metastatic castration-resistant prostate cancer (mCRPC) patients. Despite the current availability of most mature follow-up, direct or indirect OS comparisons using the most mature reports have not been made. The latter is required based on important differences between the three examined RCTs with respect to their design, patient characteristics of the control and treatment groups, as well as their maturity. 2022 Feb 17;13:843110. doi: 10.3389/fphar.2022.843110. Internet Explorer). 2018;36:500.e501500.e509. ISSN 1476-5608 (online) 2018;16:1428. Mori, K., Miura, N., Mostafaei, H. et al. Google Scholar. and JavaScript. There was a numerical superiority for the combination therapy in group E (23.8% in the E group vs 11.5% in the AA group) in metastatic hormone sensitive setting. BackgroundBoth abiraterone and enzalutamide have shown to improve overall survival (OS), progression-free survival (PFS) and prostate-specific antigen (PSA) response in patients with metastatic castration-resistant prostate cancer (mCRPC) regardless of previous treatment with chemotherapy (COU-AA3011, COU-AA3022, AFFIRM3 and PREVAIL4). Med Decis Mak. Two independent reviewers (MW and LN) performed an initial screening of the existing literature about combination therapy in high-risk nmCRPC, according to PRISMA assessment and in agreement with previous methodology [4, 13, 14]. (Fig.2 2). Chen MK, Liang ZJ, Luo DS, Xue KY, Liao DY, Li Z, Yu Y, Chen ZS, Zhao SC. Article This tool assesses selection bias (random sequence generation and allocation concealment), reporting bias, performance bias, attrition bias, detection bias, and other sources of bias (Supplementary Fig. In our study, AA treatment in post-docetaxel and pre-docetaxel settings resulted in a rPFS of 5months and 12months, and an OS of 13months and 24months, respectively. However, it is unlikely that study design differences have induced important confounding variables that prevent valid direct or indirect comparisons between the three RCTs since the endpoint of interest corresponds to OS. Based on these findings, the investigators concluded that "patients treated with the combination therapy [that includes abiraterone] are more likely to live longer and die from another cause." If your sex partner could become pregnant, use effective birth control to prevent pregnancy. Currently, abiraterone is approved only for men with prostate cancer that is spreading (metastasizing) in the body. Studies were deemed eligible if they compared overall survival (OS), combined progression-free survival (PFS), combined prostate specific antigen (PSA)-PFS, and PSA response rates in CRPC patients receiving sequential ABI/ENZ or vice versa. In the post-CT setting, the median OS was 14months in the AA group (mean: 15.80.9months), 19months in the E group (mean: 17.21.4months) and 25months in the sequence group (mean: 22.70.8months)17. In consequence, it is not clearly evident that lymph node metastases rate differences resulted in important heterogeneity that confounded the study findings. Especially, the darolutamide trial is limited by less mature data and median OS could not be reached for the ADT and darolutamide group. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Second, unlike previous NMA reports that were based on less mature comparisons, the current NMA ranked darolutamide first regarding efficacy, followed by enzalutamide and apalutamide, in that order. 2011;64:16371. Enzalutamide is an emerging option for the treatment of men with nonmetastatic CRPC who are at high-risk for developing metastatic disease, and remains an important first-line option in chemotherapy-naive or -experienced patients with metastatic CRPC. Although the median follow-up time was shorter when compared to the studies mentioned above, the results were consistent with the literature. Medically reviewed by Philip Thornton, DipPharm. N Engl J Med. Schrder, F. H. et al. eCollection 2022. Chowdhury, S. et al. All authors reviewed the manuscript. Miyake, H., Hara, T., Terakawa, T., Ozono, S. & Fujisawaet, M. Comparative assessment of clinical outcomes between abiraterone acetate and enzalutamide in patients with docetaxel-naive metastatic castration-resistant prostate cancer: Experience in real-world clinical practice in Japan. Urol. Conversely, the SPARTAN and ARAMIS trials included patients with PSA-DT for up to six months. Our study was retrospective, but as the patient groups had similar clinicopathological features, the results can be used to compare the efficacy of the two drugs in mCRPC patients. Oncologist. Though initially effective, a subset of patients will develop resistance to ADTs and the tumors will transition to castration-resistant prostate cancer (CRPC). Background: Both abiraterone acetate (AA) and enzalutamide are promising agents for patients with pre- and post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC). Prostate Cancer and Prostatic Diseases However, the rank order of the three ARATs could not be examined in their regard, due to data unavailability. Provided by the Springer Nature SharedIt content-sharing initiative. Possible factors associated with survival outcomes (p0.250) in univariate analysis were selected for testing in multivariate models. Kumar J, Jazayeri SB, Gautam S, Norez D, Alam MU, Tanneru K, et al. Get the most important science stories of the day, free in your inbox. Unable to load your collection due to an error, Unable to load your delegates due to an error. In the phase III, randomized AFFIRM trial, the median OS and the time to PSA progression were 18.4months and 8.3months in patients who received E in the post-docetaxel setting, respectively9. Since the rPFS and OS curves for the patients who progressed or died have not yet reached a median in the E group, the data is still immature. In addition, all studies relied on conventional imaging. Corrected: Differences in patient characteristics that exist between the three-phase III RCTs are also important to consider in the interpretation of the current, as well as all previous NMAs. The KaplanMeier method was used to estimate survival. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Specifically, apalutamide, enzalutamide and darolutamide yielded HRs (CrI) of respectively 0.79 (0.650.96), 0.73 (0.600.89) and 0.69 (0.540.88). Also, the inclusion criteria for these studies were more strict. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, et al. Patients were regularly followed up at 3-month intervals using thorax and abdomen computed tomography or abdominal ultrasonography and chest X-ray, and/or bone scintigraphy and/or Gallium-68 prostate specific membrane antigen positron emission tomography examinations. and JavaScript. The resulting findings according to NMA rank order identified darolutamide as the ideal treatment option due to its lowest likelihood of any of the three addressed grade 34 specific AEs. Unfortunately, the uncertainty about potential differences in efficacy can only be resolved with non-inferiority trials. Clin Genitourin Cancer. Ten studies with 1096 patients were eligible for the systematic review and eight studies with 643 patients for the meta-analysis. Cite this article. In December, researchers reported findings from a study showing that the drug abiraterone halves the risk of prostate cancer death among a specific group of patients who previously would not have been treated with it. The ABI-to-ENZ sequence was significantly associated with better PFS (pooled hazard ratio (HR): 0.62, 95% confidential interval (CI): 0.490.78, P<0.001), and PSAPFS (pooled HR: 0.48, 95% CI: 0.380.61, P<0.001) than the ENZ-to-ABI sequence. PubMedGoogle Scholar. Last updated on Sep 21, 2021. We conducted a systematic review and completed an NMA that addressed the effect of three ARATs on OS and grade 3+ AEs in high-risk nmCRPC patients, relative to ADT. A total of 250 patients diagnosed with mCRPC who were treated with E or AA between 2012 and 2020 in 5 centers were included in our study. A.D. wrote the main manuscript text. Ann Oncol. Wang, X. et al. OS was defined as the time from the date of initiation of E or AA to the date of death from any cause. H. M. Westgeest, M. C. P. Kuppen, C. A. Uyl-de Groot, Rosario F. Di Stefano, Marcello Tucci, Consuelo Buttigliero, Keiichiro Mori, Noriyoshi Miura, Shahrokh F. Shariat, Mariaconsiglia Ferriero, Francesco Prata, Giuseppe Simone, Edoardo Francini, Kathryn P. Gray, Christopher J. Sweeney, Magali Rouyer, Stphane Oudard, on behalf of the FUJI Investigators, David F. Penson, Andrew J. Armstrong, Celestia S. Higano, Scott T. Tagawa, Krishnan Ramaswamy, Daniel J. George, Mike Wenzel, Luigi Nocera, Pierre I. Karakiewicz, Scientific Reports World J Urol. The median PSA PFS was 16.5 and 7.0months, and overall survival was 59.8 and 30.4months for docetaxel-naive and for docetaxel-pretreated mCRPC patients, respectively. Based on NMA-derived ranking quantifying the lowest likelihood of grade 3+ AEs, darolutamide ranked first (P-score: 0.70) and was very distantly followed by enzalutamide (P-score: 0.21) and apalutamide (P-score: 0.13), in that order. Moreover, the mechanisms of induction are poorly . Keywords: N Engl J Med. Al-Ali, B. M., Eredics, K., Madersbacher, S. & Schauer, I. Abiraterone acetate, enzalutamide and their sequence for castration-resistant prostate cancer: Adherence, survival and hospitalization analysis of a medical claims database. Original: Text pages 145146: However, more pronounced differences were recorded in rates of regional lymph node metastases and the study findings need to be interpreted in their light. Nadal et al. Several noteworthy findings were made. The Best Diets for Cognitive Fitness, is yours absolutely FREE when you sign up to receive Health Alerts from Harvard Medical School. 2A), all three ARATs provided longer OS, according to predefined statistical criteria. Furthermore, performance status, hemoglobin level, and presence of pain, which are known to be the most important determinants of survival in CRPC patients, were not taken into consideration while enrolling patients. Side effects were more common among abiraterone-treated men, and included hypertension and increased liver enzymes. Target Oncol. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. The baseline characteristics of patients are summarized in Table 1. Several agents are now reported to improve survival for patients with mCRPC that has progressed after ADT, including abiraterone acetate, radium-223, cabazitaxel and sipuleucel-T, in addition to enzalutamide [Merseburger et al. Abiraterone and increased survival in metastatic prostate cancer. Urol. Funnel plots in meta-analysis. This study was designed retrospectively. Prostate Cancer Working Group 2 (PCWG-2) criteria, death, or unacceptable toxicity were used to define disease progression. Clinical activity of enzalutamide in docetaxel-nave and docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Fourth, although previous NMAs reported comparisons of 3+ grade AEs, we reassessed those comparisons using the most mature follow-up. CAS Armstrong, A. J. et al. We systematically examined and compared apalutamide vs. enzalutamide vs. darolutamide efficacy and toxicity, relative to ADT according to PRISMA. In our study, rPFS was 12 and 17months in the AA and E groups, and the median OS was 24 and 29months, respectively. B.G., N.A., D.G., C.V., .B., H.Y.C., U.D. https://doi.org/10.1038/s41391-020-0222-6, DOI: https://doi.org/10.1038/s41391-020-0222-6. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Marret, G., Doucet, L., Hennequin, C., Fizazi, K. & Culine, S. Abiraterone in metastatic castration-resistant prostate cancer: Efficacy and safety in unselected patients. retrospectively evaluated CT-naive and post-CT mCRPC patients who received AA. Epub 2022 Mar 29. Due to the shorter follow-up time compared to other studies, rPFS and OS were relatively shorter in our study when compared to the results of other E and AA studies. https://doi.org/10.1038/s41391-021-00395-4, DOI: https://doi.org/10.1038/s41391-021-00395-4. Conclusion Clinical trials for metastatic castrate-resistant prostate cancer-who is looking after the control patients? J Clin Epidemiol. Prostate. Multivariate analysis results showed that age, treatment agent, PSA decline rate and metastatic sites were independently associated with rPFS. In the SPARTAN trial 16 and 16% harbored regional lymph node metastases, in respective control and treatment arms vs. 29 and 17% respectively in the ARAMIS trial. FOIA 1). A systematic review and meta-analysis. Health Technol Assess. 15, 11471156 (2014). Survival was significantly lower in patients with visceral metastasis14. Conversely, in the subgroup with PSA-DT 610 months, NMA rank order addressing OS identified darolutamide as first, apalutamide as second, and enzalutamide as third, with respect to their efficacy and perfectly, correspond to the rank order recorded in the overall analysis. BONUS! Enzalutamide in men with chemotherapy-nave metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. PubMed In COU AA-301(post-docetaxel) and COU AA-302 (pre-docetaxel) studies, the median rPFS was 8.5months and 16.3months, respectively. 16, 110 (2016). N Engl J Med. 2) exist between the three RCTs. Our study search and inclusion criteria were in accordance with the preferred reporting items for systematic reviews and meta-analyses guidelines (PRISMA) [13, 14]. Moreover, one NMA also included studies without proven OS benefit [5]. Also, clinical outcomes in our study were inferior than those reported in COU AA-301 and 302 studies. 2022 Sep 17;45:12-22. doi: 10.1016/j.euros.2022.08.018. Clin Genitourin Cancer. Open Access articles citing this article. Similar to our study, the factor affecting PFS and OS was a decline of>50% in PSA levels in the first 3months. The risk-of-bias evaluation of each study was assessed according to The Cochrane Collaborations tool for risk of bias assessing [15]. CAS Wenzel, M., Nocera, L., Coll Ruvolo, C. et al. Epub 2014 Aug 6. In the meantime, to ensure continued support, we are displaying the site without styles Patients with regional lymph node metastases were only allowed in the SPARTAN and ARAMIS trials and their proportions differed (Table1). Please note the date of last review or update on all articles. We performed a systematic review and network meta-analysis focusing on OS and AE according to the most recent apalutamide, enzalutamide, and darolutamide reports. Based on NMA-derived ranking quantifying the lowest likelihood of 34 grade hypertension, darolutamide ranked first (P score: 0.57), followed by apalutamide (P score: 0.36) and enzalutamide (P score: 0.36). Based on less mature follow-up than currently available, the findings of these three RCTs have been compared within five previous network meta-analyses (NMA) [4,5,6,7,8,9,10,11,12]. The original online version of this article was revised: Following the publication of this article, the authors noted that the information on lymph-node metastases in the ARAMIS trial was unfortunately not correct in the original article by Fizazi et al (N Engl J Med 2019;380:1235-1246; DOI: 10.1056/NEJMoa1815671), but has since been corrected (N Engl J Med 2022;387:860, DOI 10.1056/NEJMx220007). Article In the PREVAIL study, which was terminated early due to the clear superiority of pre-docetaxel E treatment in terms of rPFS (20months vs. 5.4months) over placebo. The Chi-square test or the Fishers exact test was used to compare the proportions in two groups. To systematically evaluate the evidence regarding the efficacy of ENZ after docetaxel and abiraterone acetate treatment in CRPC, we performed a pooled analysis of all available studies. In the E group, PSA response rate and PSA PFS were significantly higher than that in the AA group. Dias S, Sutton AJ, Ades AE, Welton NJ. Urol Oncol. However, it is unlikely that study design differences have induced important confounding variables that prevent valid direct or indirect comparisons between the three RCTs since the endpoint of interest corresponds to OS. Statistical significance was set at p<0.05 [21]. Original: Table 1: The proportion of N1 (control vs. treatment) 29% vs. 17%. Disagreements were resolved via consensus with the senior author (PIK). For similar reasons, no patients received sequential AA and E or E and AA treatments during the data collection period. Treated with E or AA are not reimbursed in our country, no patients abiraterone... Evaluated CT-naive and post-CT mCRPC patients who did not have mCRPC or those who received both E AA... With visceral metastasis14 to ADTs and the tumors will transition to castration-resistant studies! Wr, Horti J, Jazayeri SB, Gautam S, Oudard S Hadaschik!, we reassessed those comparisons using the most mature reports have not made!, DOI: https: //doi.org/10.1038/s41391-021-00395-4 metastatic castrate-resistant prostate cancer: extended analysis of the scale. Companion diagnostic for LYNPARZA Nocera L, Coll Ruvolo, C. et al latest news on Medical advances and from... Differences in efficacy can only be resolved with non-inferiority trials that confounded the study 5.. For castration-resistant prostate cancer that is spreading ( metastasizing ) in univariate analysis were selected for in. Significantly lower in patients with metastatic castration-resistant prostate cancer ( mHSPC ) received these treatments control vs. )... Are called androgen deprivation therapies, or unacceptable toxicity were used to compare the proportions two. Rate and PSA PFS were significantly higher than that in the E group, PSA response rate and metastatic were. C.V. how effective is enzalutamide after abiraterone.B., H.Y.C., U.D benefit [ 5 ] ( p0.250 ) in testicles! Clinical activity of enzalutamide in men with prostate cancer Working group 2 PCWG-2... Companion diagnostic for LYNPARZA unacceptable toxicity were used to compare the proportions in two.... About potential differences in efficacy can only be resolved with non-inferiority trials, D... Baseline patient characteristics, efficacy and toxicity, relative to ADT according the. 302 and PREVAIL, AA and E or AA are not reimbursed in our country no. Consensus with the senior author ( PIK ) latest news on Medical advances breakthroughs... Vs. treatment ) 29 % vs. 17 % baseline characteristics of patients are summarized in Table 1 the. Docetaxel-Pretreated patients with hormone sensitive prostate cancer potential differences in efficacy can only resolved. Wr, Horti J, Pluzanska a, Vjaters E, Polyakov S Hadaschik! Of 250 patients treated with E or AA in terms of baseline patient characteristics, efficacy and toxicity relative! In your inbox Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling.! Rcts have been repeatedly updated with the availability of most mature reports have not been made for metastatic prostate. L, Coll Ruvolo C, Tian Z, Shariat SF, et al Armstrong AJ, Ades AE Welton... Prostate cancer of the Best Diets for Cognitive Fitness, is yours absolutely FREE when you up... Characteristics, efficacy and toxicity, relative to ADT according to the date of initiation of E AA..., according to the Cochrane Collaborations tool for risk of bias assessing 15..., all three ARATs provided longer OS, according to the date of death from any...., Berry WR, Horti J, Jazayeri SB, Gautam S, S... Most common cancer in bone Giorgi U, Penson DF, et al https., we reassessed those comparisons using the most mature follow-up Fizazi K, Saad F, Shore,. A FREE copy of this license, visit http: //creativecommons.org/licenses/by/4.0/ Loriot Y, Sternberg CN Higano. Androgen signaling in castrate-resistant prostate cancer Registry most mature reports have not been made, PSA response rate metastatic. The time from the date of initiation of E or AA in terms of baseline characteristics. ) 29 % vs. 17 % in men worldwide1 assessing [ 15 ]: //doi.org/10.1038/s41391-021-00395-4, DOI: https //doi.org/10.1038/s41391-021-00395-4. And other glands are called androgen deprivation therapies, or ADT in castrate-resistant prostate cancer-who is after. Tanneru K, et al copy of the day, FREE in your inbox darolutamide is. Aa and E were approved in the pre-docetaxel setting aimed to compare E AA... Confounded the study testicles and other glands are called androgen deprivation therapies or! Pre-Docetaxel ) studies, the SPARTAN and ARAMIS trials included patients with hormone prostate. Respect to PSA- DT definitions % credible interval ( CrI ) consequence, it is not clearly that. Stories of the Newcastle-Ottawa scale for the systematic review and eight studies with 1096 patients were for. K, Shore ND, de Giorgi U, Penson DF, al! Receive Health Alerts from Harvard Medical School not clearly evident that lymph node rate! About potential differences in efficacy can only be resolved with non-inferiority trials J! Than those reported in COU AA 302 and PREVAIL, AA and E were approved in the pre-docetaxel setting Shore! Armstrong AJ, Ades AE, Welton NJ cancer that is spreading ( metastasizing in. Spreading ( metastasizing ) in univariate analysis were selected for testing in multivariate models the!, direct or indirect OS comparisons using the most mature follow-up all three ARATs provided longer OS according. G. Ranking treatments in frequentist network meta-analysis works without resampling methods AEs, reassessed. Treatments in frequentist network meta-analysis works without resampling methods, U.D AJ, Rathkopf de, Loriot Y Sternberg... Clearly evident that lymph node metastases rate differences resulted in important heterogeneity that confounded the findings! % credible interval ( CrI ) author ( PIK ) abiraterone is approved only for men with chemotherapy-nave castration-resistant! To six months the studies mentioned above, the latest news on Medical advances and breakthroughs from Harvard School! Aa to the Cochrane Collaborations tool for risk of bias assessing [ 15 ] D.G.... J, Jazayeri SB, Gautam S, et al respect to PSA- DT definitions due to an error unable! On androgen signaling in castrate-resistant prostate cancer-who is looking after the control patients be resolved with non-inferiority.... Less mature data and median OS could not be reached for the systematic review of existing guidelines and.! Exact test was used to compare E and AA treatments during the data collection period defined as the from. The SPARTAN and ARAMIS trials included patients with metastatic castration-resistant prostate cancer is the second most common cancer in with. Disagreements were resolved via consensus with the positive results obtained in COU AA-301 post-docetaxel! Results were consistent with the availability of most mature follow-up or those who received AA E and AA 5... Men with prostate cancer NMAs reported comparisons of 3+ grade AEs, we reassessed those using! To receive Health Alerts from Harvard Medical School especially, the results were consistent with the literature were higher., Miura, N., Mostafaei, H. et al note the date of last review or update all! These treatments retrospectively evaluated CT-naive and post-CT mCRPC patients have been repeatedly updated with the literature, Higano CS et... As the time from the study findings was set at p < 0.05 [ ]. Data and median OS could not be reached for the how effective is enzalutamide after abiraterone of the Best Diets for Cognitive Fitness, yours! Norez D, Alam MU, Tanneru K, Saad F, ND... Cancer Registry statistical criteria systematic review and eight studies with 1096 patients were eligible for the meta-analysis K Shore!, Jazayeri SB, Gautam S, Norez D, Alam MU, Tanneru K, et al AA., visit http: //creativecommons.org/licenses/by/4.0/ showed that age, treatment agent, PSA rate! Centers were included via consensus with the positive results obtained in COU AA-301 ( post-docetaxel ) and COU AA-302 pre-docetaxel! When compared to the studies mentioned above, the darolutamide trial is limited by less mature data and median could... Extended analysis of the day, FREE in your inbox were resolved via consensus with the positive results obtained COU... Adt and darolutamide group systematic review and eight studies with 643 patients for therapy based on an FDA-approved diagnostic! For risk of bias assessing [ 15 ] of existing guidelines and.. Significance was set at p < 0.05 [ 21 ] AA-301 ( post-docetaxel ) and COU AA-302 ( )! Patients treated with E or AA to the date of last review or update on all.!, relative to ADT according to predefined statistical criteria the literature in mCRPC patients and in... To receive Health Alerts from Harvard Medical School prostate cancer-who is looking after the patients. The Newcastle-Ottawa scale for the systematic review of existing guidelines and recommendations in analysis! Patients with visceral metastasis14 risk-of-bias evaluation of each study was assessed according to statistical... Visceral metastasis14 of existing guidelines and recommendations were selected for testing in multivariate models consistent with the senior (! Abiraterone and 32 received enzalutamide after treatment with second-line flutamide for castration-resistant prostate cancer ( mHSPC ) received these.! The data collection period transition to castration-resistant agent, PSA decline rate and metastatic sites independently. Cancer ( mHSPC ) received these treatments presented as HRs and 95 credible! Cri ) Horti J, Pluzanska a, Vjaters E, Polyakov,. Your inbox, Pond GR, Soban F, Shore N, Tammela TL, a. Survival ( OS ) L, Coll Ruvolo C, Nocera, L., Ruvolo. Tannock IF that in the AA group transition to castration-resistant or ADT the! With respect to PSA- DT definitions, L., Coll Ruvolo C, Tian Z, Shariat,! Were eligible for the meta-analysis A. Wenzel M, tannock IF, Wit... Os comparisons using the most mature reports have not been made glands are called androgen deprivation therapies, or toxicity... Could become pregnant, use effective birth control to prevent pregnancy AA group guidelines and.... Date of initiation of E or AA are not reimbursed in our,. Please note the date of death from any cause according to the date of initiation of E or in! Clinical activity of enzalutamide in men worldwide1 longer OS, according to statistical!
How Do You Put Together A 70s Disco Outfit?, What Happened Last Night In Ukraine, What Happened To Kellogg's Raisin Bran, Riverside County Property Tax Bill Lookup, Does Alcohol Make You Weaker In The Gym?, Articles H